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Rheumatoid Factor as a Potentiator of
Anti–Citrullinated Protein Antibody–Mediated
Inflammation in Rheumatoid Arthritis
Jeremy Sokolove,1 Dannette S. Johnson,2 Lauren J. Lahey,1 Catriona A. Wagner,1
Danye Cheng,1 Geoffrey M. Thiele,3 Kaleb Michaud,3 Harlan Sayles,3 Andreas M. Reimold,4
Liron Caplan,5 Grant W. Cannon,6 Gail Kerr,7 Ted R. Mikuls,3 and William H. Robinson1
Objective. The co-occurrence of rheumatoid factor
(RF) and anti–citrullinated protein antibody (ACPA)
positivity in rheumatoid arthritis (RA) is well described.
However, the mechanisms underlying the potential interaction between these 2 distinct autoantibodies have
not been well defined. The aim of this study was to
evaluate the epidemiologic and molecular interaction of
ACPAs and RF and its association with both disease
activity and measures of RA-associated inflammation.
Methods. In a cohort of 1,488 US veterans with
RA, measures of disease activity and serum levels of
cytokines and multiplex ACPAs were compared between
the following groups of patients: double-negative (anti–
cyclic citrullinated peptide [anti-CCP]ⴚ/RFⴚ), anti-

CCPⴙ/RFⴚ, anti-CCPⴚ/RFⴙ, or double-positive (antiCCPⴙ/RFⴙ). Additional studies were performed using
an in vitro immune complex (IC) stimulation assay in
which macrophages were incubated with ACPA ICs in
the presence or absence of monoclonal IgM-RF, and
tumor necrosis factor ␣ production measured as a
readout of macrophage activation.
Results. Compared with the double-negative subgroup (as well as each single-positive subgroup), the
double-positive subgroup exhibited higher disease activity as well as higher levels of C-reactive protein and
inflammatory cytokines (all P < 0.001). In vitro stimulation of macrophages by ACPA ICs increased cytokine
production, and the addition of monoclonal IgM-RF
significantly increased macrophage tumor necrosis factor ␣ production (P ⴝ 0.003 versus ACPA ICs alone).
Conclusion. The combined presence of ACPAs
and IgM-RF mediates increased proinflammatory cytokine production in vitro and is associated with increased
systemic inflammation and disease activity in RA. Our
data suggest that IgM-RF enhances the capacity of
ACPA ICs to stimulate macrophage cytokine production, thereby providing a mechanistic link by which
RF enhances the pathogenicity of ACPA ICs in RA.
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Rheumatoid arthritis (RA) is often characterized
by the presence of circulating autoantibodies. Rheumatoid factor (RF) was first described more than 50 years
ago (1–3) and is detectable in nearly 70% of patients
with RA, although its presence is not specific for
RA (4,5). Nevertheless, whether RF plays a role in RA
pathogenesis has remained unclear. More recently, attention has been given to anti–citrullinated protein
antibodies (ACPAs). Anti–cyclic citrullinated peptide
(anti-CCP) assays are commonly used to test for
ACPAs, which are detectable in ⬃70% of patients with
813
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RA and are highly specific for RA (6). In addition to
their use in diagnostic criteria, RF and ACPAs provide
important prognostic information.
Previous studies have examined the diagnostic
utility of RF and ACPAs (7,8), and multiple studies have
demonstrated that higher concentrations of both autoantibodies are associated with a more aggressive disease
course marked by increased disease activity and reduced
rates of remission (9–11). However, there has been little
investigation into the mechanisms by which these autoantibodies could interact and/or contribute to RA pathogenesis. Although several in vitro (12–14) and in vivo
(15) studies have identified a potential role for ACPAs
in disease pathogenesis, the role of RF in RA pathogenesis remains elusive. In this study, we sought to investigate the role of RF as a contributor to the RA inflammatory burden, both independently and in synergy with
ACPAs.
PATIENTS AND METHODS
Patient samples and clinical measures. Study subjects
included US veterans enrolled in the Veterans Affairs Rheumatoid Arthritis (VARA) registry, with sites across the US
(16). The registry has received Institutional Review Board
approval at each site, and the Stanford Institutional Review
Board approved the biomarker and in vitro analyses performed
using RA samples. All patients satisfied the 1987 American
College of Rheumatology classification criteria for RA (17)
and provided informed written consent and Health Insurance
Portability and Accountability Act authorization. The study
group comprised 1,488 veterans with RA (89% male); detailed
characteristics of the cohort are shown in Table 1. Banked
serum samples were available for a representative population
of 1,466 patients and were used for multiplex cytokine and
autoantibody analyses.
In addition to banked sera, VARA collects clinical
data including the baseline and longitudinal 28-joint Disease
Activity Score (DAS28) values (18), as well as baseline measurements of ACPAs, obtained using a Diastat secondgeneration CCP-2 antibody enzyme-linked immunosorbent
assay (ELISA) (positivity ⱖ5 units/ml; Axis-Shield). VARA
also collects RF (positivity ⱖ15 IU/ml) and high-sensitivity
C-reactive protein (hsCRP) test results, as determined by
nephelometry (Siemens). HsCRP concentrations were not
available at followup visits. Although VARA is a multicenter
project, standardized autoantibodies are measured at the
laboratory of a single investigator (GMT). HLA–DRB1 genotyping was conducted as previously described (19). Patients
were categorized as being positive or negative for HLA–DRB1
shared epitope (SE)–containing alleles and HLA–DR3 alleles.
Followup measures include tender and swollen joint
counts in 28 joints, erythrocyte sedimentation rate (ESR;
mm/hour), pain score (range 0–10), Multidimensional Health
Assessment Questionnaire (MD-HAQ) score (range 0–3) (20),
patient’s and provider’s global assessments (range 0–100), and
treatments. A comorbidity count (range 0–9) was calculated

for each patient, using administrative codes (21). Because we
were investigating the association of autoantibodies with followup clinical parameters, patients were excluded if autoantibody or DAS28 data were unavailable, if only a single clinical
observation was recorded, or if the total followup duration was
⬍6 months.
Multiplex cytokine analysis. Multiplex analysis of cytokines and chemokines in human serum was performed using
a Bio-Plex Pro Human Cytokine 17-plex Assay (Bio-Rad) run
on a Luminex 200 system according to the manufacturer’s
instructions, with the exception that a proprietary Bio-Rad
assay dilution buffer was modified to contain reagents demonstrated to reduce the effects of heterophilic antibodies in
multiplex immunoassays, as previously described (21). Data
processing was performed by using Bio-Plex Manager 5.0
software, and analyte concentrations (picograms per milliliter)
were interpolated from standard curves.
Multiplex autoantigen arrays. Antibodies targeting
37 putative RA-associated autoantigens were measured using a
custom bead-based immunoassay on a Bio-Plex platform, as
previously described (22,23). Of the 37 antigens, 30 are citrullinated and 7 are native (native histone 2A, histone 2B,
apolipoprotein A-I [Apo A-I], filaggrin 48–65 peptide, vimentin, fibrinogen, and Apo-AI 231–248 peptide). Briefly, serum
was diluted and mixed with spectrally distinct florescent beads
conjugated with putative RA-associated autoantigens, followed by incubation with anti-human phycoerythrin–labeled
antibody and analysis on a Luminex 200 instrument.
In vitro ACPA immune complex (IC) stimulation
assays. ACPA IC stimulation of human macrophages was
performed as previously described (12). Polyclonal rabbit IgG
antibodies against fibrinogen (Pierce) or human IgG derived
from patients with ACPA-positive RA (RA lgG) was used to
generate plate-bound ICs containing citrullinated fibrinogen
ICs. RA IgG derived from 3 pooled plasma samples that were
shown by ELISA to contain high levels of anti–citrullinated
fibrinogen antibodies was purified by affinity chromatography
on protein G columns, according to the instructions of the
manufacturer (Pierce).
Monoclonal IgM-RF derived from a lymphoblastoid
cell line generated from a patient with RA (24) was a generous
gift from Drs. Michael Steinitz and Reuven Laskov (Hebrew
University, Jerusalem, Israel). IgM-RF was isolated from cell
culture supernatant by ammonium sulfate precipitation,
washed, and dialyzed against phosphate buffered saline (PBS).
The resultant product was shown to contain primarily IgM,
with no contamination by human IgG. This antibody has been
demonstrated to bind human and rabbit IgG but not IgM and,
when bound to ICs, fails to bind complement (25). Additional
monoclonal IgM antibodies with in vitro RF activity that were
isolated from patients with mixed cryoglobulinemia were generously provided by Dr. Mariana Newkirk (McGill University,
Montreal, Quebec, Canada).
The purified RA IgG and monoclonal RF were separately concentrated by centrifugation over a 100-kd molecular
weight filter column with buffer exchange to PBS (Amicon
Ultra; Millipore) and were depleted of endotoxin by filtration
through a polymyxin B column (Detoxi-Gel; Pierce). RA IgG
and IgM-RF concentrations were estimated according to optical density at 280 nm, aliquoted, and stored at ⫺80°C. For
generation of citrullinated fibrinogen ICs, flat-bottomed
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Table 1. Characteristics of the patients with RA at the time of study enrollment*

Characteristic
Sociodemographics and comorbidity
Age, mean ⫾ SD years
Male sex
Race/ethnicity
White
African American
Other
High school education or higher
Comorbidity count, mean ⫾ SD
RA factors
Ever smoking†
HLA–DRB1 SE positive†
2 HLA–DRB1 alleles
HLA–DR3†
Age at diagnosis, mean ⫾ SD years†
Disease duration, mean ⫾ SD years‡
Prednisone treatment
Methotrexate treatment‡
Biologic agent treatment
Nodules†

Concordant
seronegative
(n ⫽ 206)

Anti-CCP⫹/RF⫺
(n ⫽ 102)

Anti-CCP⫺/RF⫹
(n ⫽ 134)

Concordant
seropositive
(n ⫽ 1,046)

64.5 ⫾ 12.2
89.3

61.2 ⫾ 11.9
88.2

63.3 ⫾ 11.9
91.8

63.0 ⫾ 11.2
91.1

79.6
15.1
5.3
86.7
2.6 ⫾ 1.6

75.5
16.7
7.8
86.7
2.2 ⫾ 1.5

76.9
15.7
7.7
85.6
2.4 ⫾ 1.5

76.7
16.7
6.6
84.0
2.3 ⫾ 1.6

73.2
54.6
8.7
25.6
55.9 ⫾ 15.0
8.7 ⫾ 10.1
35.0
45.4
16.9
12.1

73.4
77.8
23.2
14.1
50.7 ⫾ 13.7
10.5 ⫾ 10.7
40.7
64.8
24.2
24.5

73.9
54.4
6.5
32.6
53.8 ⫾ 13.7
9.5 ⫾ 10.7
40.7
51.2
23.6
26.1

82.7
76.5
24.7
12.8
51.8 ⫾ 13.6
11.2 ⫾ 11.4
45.2
49.7
21.1
33.8

* Except where indicated otherwise, values are the percent. RA ⫽ rheumatoid arthritis; anti-CCP ⫽ anti–cyclic
citrullinated peptide; RF ⫽ rheumatoid factor; SE ⫽ shared epitope.
† Overall P ⬍ 0.001, by analysis of variance.
‡ Overall P ⬍ 0.01, by analysis of variance.

96-well culture plates were coated overnight at 4°C with 50 l
of citrullinated fibrinogen (20 g/ml), washed in PBS containing 0.05% Tween 20, and incubated for 2 hours at 4°C with
100 l of polyclonal rabbit antibodies against fibrinogen
(50 g/ml), 100 l of anti–citrullinated fibrinogen–positive IgG
(10 mg/ml), or 100 l of anti–citrullinated fibrinogen–positive
IgG preincubated with monoclonal IgM-RF (stock concentration 5 mg/ml used at 1:20 or 1:100 dilution); PBS alone was
used as a control. Wells were again washed in PBS containing
0.05% Tween 20, and macrophages (50,000/well) in 200 l of
RPMI containing 5% fetal calf serum were then added to the
wells and incubated for 16 hours, at which time levels of tumor
necrosis factor ␣ (TNF␣) in culture supernatant were measured by ELISA (PeproTech). All in vitro cell stimulations
were performed in triplicate and in at least 2 separate experiments. Levels of TNF␣ production from in vitro macrophagestimulation assays were compared using Student’s unpaired
t-test.
Statistical analysis. Patients were categorized into the
following groups: double-negative (anti-CCP⫺/RF⫺; n ⫽
206), anti-CCP⫹/RF⫺ (n ⫽ 102), anti-CCP⫺/RF⫹ (n ⫽ 134),
and double-positive (anti-CCP⫹/RF⫹; n ⫽ 1,046). Comparisons of patient characteristics were examined according to
autoantibody subgroup, using chi-square tests or analysis of
variance (ANOVA). Unadjusted comparisons of the 8 continuous disease activity measures assessed at enrollment were
examined using one-way ANOVA with Tukey’s post hoc test to
compare each of the 4 subgroups. Levels of each cytokine as
well as hsCRP were compared between the double-negative,
anti-CCP⫹/RF⫺, anti-CCP⫺/RF⫹, and double-positive subgroups, using the Kruskal-Wallis test with Dunn’s post hoc test.

The ESR was log-transformed prior to analysis to render a
more normal distribution. Given the skewed distributions, joint
counts were dichotomized into 0 tender/swollen joints and
ⱖ1 tender/swollen joints, with comparisons examining the
probability of having a joint count of ⬎0. Continuous joint
counts were reported for descriptive purposes.
We examined whether the associations observed between autoantibody status and disease activity at enrollment
were independent of other covariates, and whether these
associations were apparent over an extended period of observation. For multivariable analyses, double-negative cases
served as the referent population. Generalized linear mixed
models were used to evaluate multivariable associations of
autoantibody group with disease activity assessed during followup. The generalized linear mixed models adjusted for the
random effects from sites and correlations between the outcomes from the same patient over time via a compound
symmetry correlation structure. Analyses were completed using Stata version 12, SAS version 9.3, and GraphPad Prism
version 5.
Additional comparisons were performed on multiplex
cytokines as well as multiplex ACPAs, using SAM (Significance Analysis of Microarrays) version 3.08 (24). Output was
sorted based on false discovery rates (FDRs) in order to
identify the antigens with the greatest differences in autoantibody reactivity between serologic subgroups. The use of FDRs
obviates the need to adjust for multiple comparisons. Hierarchical clustering was performed using Cluster 3.0 to arrange
the SAM results according to similarities among autoantibody
specificities, and the results were displayed using Java TreeView (version 1.1.3).
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RESULTS
ACPAs and RF in the VARA cohort. The characteristics of the 1,488 patients are shown in Table 1. The
mean ⫾ SD followup was 3.6 ⫾ 2.8 years, with 16,822
encounters and 5,284 patient-years of observation. A
majority of the patients (⬃90%) were male, with a mean
age of ⬃63 years. Most of the patients (70%) were
anti-CCP⫹/RF⫹, 14% were anti-CCP⫺/RF⫺, 9% were
anti-CCP⫺/RF⫹, and 6.9% were anti-CCP⫹/RF⫺.
There were significant differences across the autoantibody groups for age at diagnosis, disease duration,
methotrexate treatment, and presence of nodules. Compared with the other patients, those who were antiCCP⫺/RF⫺ were older at the time of diagnosis, had a
shorter disease duration, were less likely to be receiving
methotrexate, and had a lower prevalence of nodules.
Ever smoking was more common among antiCCP⫹/RF⫹ patients (83%) compared with patients in
the other subgroups (73–74%; P ⬍ 0.001). HLA–DRB1
SE positivity was higher in groups characterized by
anti-CCP positivity (P ⬍ 0.001), irrespective of RF
status. HLA–DR3 positivity was less common among
patients positive for anti-CCP antibodies (P ⬍ 0.001 across
groups). The average anti–CCP-2 titer was nearly identical
in the CCP⫹/RF⫺ and CCP⫹/RF⫹ groups (275.85 AU
versus 273.64 AU), and similarly, the average RF titer in
the CCP⫺/RF⫹ group was nearly identical to that in the
CCP⫹/RF⫹ group (329.03 IU versus 328.12 IU).
Relationship between the concurrent presence of
ACPAs and RF and increased RA disease activity. The
double-positive group exhibited significantly higher

levels of RA disease activity, with a mean ⫾ SD baseline
DAS28 of 4.2 ⫾ 1.6 compared with 3.7 ⫾ 1.6 in the
double-negative group, 3.4 ⫾ 1.6 in the anti-CCP⫹/RF⫺
group, and 3.9 ⫾ 1.7 in the anti-CCP⫺/RF⫹ group
(overall P ⬍ 0.001, by ANOVA) (Table 2). After
adjusting for multiple comparisons across the 4 groups,
the ESR, and hsCRP and DAS28 values at the time of
enrollment were higher in the double-positive group
compared with the other groups. Post-test comparisons
between each pair of groups demonstrated significantly
higher ESRs and CRP levels among the double-positive
group compared with the double-negative, anti-CCP⫹/
RF⫺, and anti-CCP⫺/RF⫹ groups, and the DAS28 was
significantly higher in the double-positive group compared with the double-negative and anti-CCP⫹/RF⫺
subgroups, with a nonsignificant trend compared with
the anti-CCP⫺/RF⫹ subgroup.
Similarly, in multivariable models, concurrent
anti-CCP–positive and RF-positive autoantibody status
was associated with longitudinal clinical and laboratory
measures of disease activity, including the swollen joint
count, ESR, and DAS28 when compared with the
double-negative or anti-CCP⫹/RF⫺ subgroups, while
only a similar trend was noted when compared with the
anti-CCP⫺/RF⫹ subgroup (Table 3).
Concurrent presence of ACPAs and RF is predictive of RA-associated inflammation. Compared with the
double-negative group, the double-positive group exhibited significantly higher ESRs and hsCRP levels as well
as higher levels of multiple circulating inflammatory
cytokines, including TNF␣, interleukin-1␤ (IL-1␤), IL-6,

Table 2. Measures of disease activity in patients with rheumatoid arthritis at the time of study enrollment, according to autoantibody status*

Measure

Concordant
seronegative
(n ⫽ 206)

Anti-CCP⫹/RF⫺
(n ⫽ 102)

Anti-CCP⫺/RF⫹
(n ⫽ 134)

Concordant
seropositive
(n ⫽ 1,046)

Pain score (range 0–10)
MD-HAQ (range 0–3)
Tender 28 joint count
Swollen 28 joint count
Patient’s global assessment (range 0–100)
Provider’s global assessment (range 0–10)
Log-transformed ESR, mm/hour†
CRP, mg/liter‡
DAS28§

5.1 ⫾ 2.8
0.94 ⫾ 0.63
6.0 ⫾ 7.5
4.1 ⫾ 5.4
45.1 ⫾ 27.0
39.9 ⫾ 24.5
19.4 ⫾ 19.6
0.92 ⫾ 1.78
3.7 ⫾ 1.6

4.3 ⫾ 2.7
0.81 ⫾ 0.62
4.5 ⫾ 7.0
4.0 ⫾ 5.7
35.8 ⫾ 23.2
29.1 ⫾ 19.8
21.2 ⫾ 21.9
0.92 ⫾ 0.74
3.4 ⫾ 1.6

4.8 ⫾ 2.7
0.96 ⫾ 0.58
5.5 ⫾ 6.7
5.3 ⫾ 6.6
43.4 ⫾ 26.1
32.0 ⫾ 25.2
24.8 ⫾ 24.7
1.20 ⫾ 1.78
3.9 ⫾ 1.7

4.8 ⫾ 2.8
0.98 ⫾ 0.60
6.3 ⫾ 7.3
5.8 ⫾ 6.4
43.8 ⫾ 25.8
37.8 ⫾ 23.3
30.2 ⫾ 24.0
1.36 ⫾ 2.13
4.2 ⫾ 1.6

* Joint counts were dichotomized as 0 versus ⱖ1. Statistical significance, as determined by analysis of variance, was defined as P ⬍ 0.00625. Values
are the mean ⫾ SD. Anti-CCP ⫽ anti–cyclic citrullinated peptide; RF ⫽ rheumatoid factor; MD-HAQ ⫽ Multidimensional Health Assessment
Questionnaire; ESR ⫽ erythrocyte sedimentation rate; CRP ⫽ C-reactive protein; DAS28 ⫽ Disease Activity Score in 28 joints.
† P ⬍ 0.001, overall and concordant seropositive versus concordant seronegative; P ⫽ 0.007, concordant seropositive versus anti-CCP⫺/RF⫹; P ⫽
0.001, concordant seropositive versus anti-CCP⫹/RF⫺.
‡ P ⬍ 0.001, overall, concordant seropositive versus concordant seronegative and versus anti-CCP⫹/RF⫺; P ⫽ 0.01, concordant seropositive versus
anti-CCP⫺/RF⫹.
§ P ⬍ 0.001 overall; P ⫽ 0.001, concordant seropositive versus concordant seronegative and versus anti-CCP⫹/RF⫺.
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Table 3. Multivariable associations of autoantibody status with measures of disease activity in patients with RA during followup*
Discordant
Anti-CCP⫹/RF⫺
Variable

Anti-CCP⫺/RF⫹

Concordant, anti-CCP⫹/RF⫹

␤ coefficient

P

␤ coefficient

P

␤ coefficient

P

⫺0.489
⫺0.161
⫺0.251
0.100
⫺6.088
⫺3.804
0.444
⫺0.003

0.094
0.034
0.181
0.562
0.015
0.069
⬍0.001
0.987

⫺0.008
⫺0.000
0.326
0.619
⫺0.212
2.597
0.410
0.387

0.972
0.996
0.042
⬍0.001
0.925
0.191
⬍0.001
0.005

⫺0.288
⫺0.015
0.052
0.507
⫺1.588
2.418
0.652
0.418

0.097
0.725
0.624
⬍0.001
0.315
0.069
⬍0.001
⬍0.001

Pain score (range 0⫺10)
MD-HAQ (range 0⫺3)
Tender joint count (0 vs. ⬎0)
Swollen joint count (0 vs. ⬎0)†
Patient’s global assessment (range 0⫺100 mm)
Provider’s global assessment (range 0⫺100 mm)
Log-transformed ESR, mm/hour‡
DAS28§

* The models were adjusted for age, sex, disease duration, comorbidity score, race/ethnicity, and treatment, including methotrexate, prednisone, and
biologic agents. The concordant seronegative group served as the referent population. RA ⫽ rheumatoid arthritis; anti-CCP ⫽ anti–cyclic
citrullinated peptide; RF ⫽ rheumatoid factor; MD-HAQ ⫽ Multidimensional Health Assessment Questionnaire; ESR ⫽ erythrocyte sedimentation
rate; DAS28 ⫽ Disease Activity Score in 28 joints.
† P ⫽ 0.426, anti-CCP⫹/RF⫹ versus anti-CCP⫺/RF⫹; P ⫽ 0.008, anti-CCP⫹/RF⫹ versus anti-CCP⫹/RF⫺.
‡ P ⫽ 0.005, concordant seropositive versus anti-CCP⫺/RF⫹; P ⫽ 0.036, concordant seropositive versus anti-CCP⫹/RF⫺.
§ P ⫽ 0.786, concordant seropositive versus anti-CCP⫺/RF⫹; P ⫽ 0.002, concordant seropositive versus anti-CCP⫹/RF⫺.
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17 potentially independent cytokines would require a
P value of 0.0029 for significance, and this was achieved
for all of the cytokines shown in Figure 1.
Additionally, all cytokine levels were compared
between the double-negative group, the anti-CCP⫺/
RF⫹ group, and a set of double-positive patients

C

IL-12p70, and IL-17A (Figure 1) (all P ⬍ 0.001 by
ANOVA). Although it is likely that many cytokines,
including those most up-regulated in the double-positive
group, are highly related and thus not subject to a high
risk of Type I error in multiplex cytokine analysis,
stringent implementation of Bonferroni’s correction for

Figure 1. Higher serum levels of rheumatoid arthritis (RA)–associated cytokines in RA patients who were double-positive for anti–cyclic
citrullinated peptide (anti-CCP) and rheumatoid factor (RF). Patients were categorized as being double-negative (anti-CCP⫺/RF⫺; n ⫽ 204),
anti-CCP⫹/RF⫺ (n ⫽ 96), anti-CCP⫺/RF⫹ (n ⫽ 135), or double-positive (anti-CCP⫹/RF⫹; n ⫽ 1,031). Between-group comparisons were
performed using the Kruskal-Wallis test with Tukey’s multiple comparison post hoc test. ⴱ ⫽ P ⬍ 0.01; ⴱⴱⴱ ⫽ P ⬍ 0.001 versus anti-CCP⫺/RF⫺.
TNF␣ ⫽ tumor necrosis factor ␣; NS ⫽ not significant; IL-1␤ ⫽ interleukin-1␤; M-CSF ⫽ macrophage colony-stimulating factor.

matched for age, sex, and disease duration. Three-way
group comparisons were performed using SAM version
3.08 (23), and output was sorted based on FDRs.
Notably, the use of FDRs obviates the need to adjust for
multiple comparisons. Supplementary Figure 1 (available on the Arthritis & Rheumatology web site at http://
onlinelibrary.wiley.com/doi/10.1002/art.38307/abstract)
demonstrates significant up-regulation of 10 of 17 cytokines in the double-positive group compared with the
double-negative group and both the anti-CCP⫹/RF⫺
and anti-CCP⫺/RF⫹ groups.
A smaller but, in many cases, statistically significant elevation of cytokine levels (as well as some clinical
measures of disease activity) was noted in the antiCCP⫺/RF⫹ group compared with the double-negative
and anti-CCP⫹/RF⫺ groups. We hypothesized that
such elevations in the anti-CCP⫺/RF⫹ group may reflect the presence in some patients of physiologic levels
of ACPAs not detected by or below the range of the
commercial anti–CCP-2 ELISA. To support this hypothesis, we used a multiplex antigen array to assess ACPA
subspecificities that might be present in the anti-CCP⫺/
RF⫹ group. Figure 2 shows that the levels of 11 of
30 ACPAs were elevated in the anti-CCP⫺/RF⫹ group
compared with the double-negative group. Thus, we
hypothesized that low levels of ACPAs that are not
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Figure 2. Heatmap showing elevated levels of anti–citrullinated protein antibodies in the anti-CCP⫺/RF⫹ group compared with the doublenegative group. Levels of autoantibodies against 37 putative targets of the RA immune response were compared between the anti-CCP⫹/RF⫺ group
(n ⫽ 96) and the anti-CCP⫺/RF⫹ group (n ⫽ 135) using a multiplex antigen microarray. SAM software was used to sort output based on false
discovery rates in order to identify antigens with the greatest differences in autoantibody reactivity between serologic subgroups. Labels on the color
key are the fluorescence intensity relative to the average values in the evaluated cohort. Cit ⫽ citrullinated; Vim ⫽ vimentin; ApoE ⫽ apolipoprotein
E; Fil ⫽ filaggrin; FibA ⫽ fibrinogen A (see Figure 1 for other definitions).

strongly represented by the anti–CCP-2 assay may synergize with RF to induce RA-associated inflammation.
Augmentation of the stimulatory capacity of
ACPA ICs by monoclonal RF. We previously demonstrated the ability of ACPA ICs to stimulate macrophage
cytokine production via costimulation of Fc␥ receptor
and the innate immune receptor Toll-like receptor 4 (12).
To evaluate the effect of RF on ACPAs, we preincubated ACPA-containing RA IgG with monoclonal
IgM-RF before formation of ACPA ICs. As previously
described, in vitro stimulation of monocyte-derived
macrophages by ACPA ICs demonstrated increased
cytokine production (P ⫽ 0.002 versus citrullinated
fibrinogen only), and the addition of monoclonal
IgM-RF resulted in a further significant increase in
macrophage TNF␣ production as compared with ACPA
ICs alone (P ⫽ 0.003) (Figure 3A). Notably, we additionally tested 2 monoclonal IgM antibodies with in vitro
RF activity, which were isolated from patients with
mixed cryoglobulinemia. However, the addition of these
IgM antibodies at 20 g/ml, 100 g/ml, and 200 g/ml
failed to augment macrophage TNF secretion in response to ACPA ICs (data not shown).
Given the potential inclusion of IgG-RF (or
IgM-RF) in our ACPA-positive IgG preparation, we
further investigated the ability of monoclonal IgM-RF to
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IgM-RF to augment anti–citrullinated fibrinogen IC–
induced macrophage activation, as evidenced by increased cytokine production (Figure 3B).
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Figure 3. IgM-RF augments macrophage activation by anti–
citrullinated protein antibody (ACPA) immune complexes (ICs) in
vitro. Monocyte-derived macrophages were added to plates precoated
with human citrullinated fibrinogen (cFb) ICs (A) or with citrullinated
fibrinogen ICs formed using polyclonal rabbit IgG antibodies against
fibrinogen (B), in the presence or absence of monoclonal IgM-RF.
Macrophage stimulation was assessed by measuring the level of TNF␣
in harvested cell culture supernatants. Results are representative of
experiments performed at least twice. Bars show the mean ⫾ SEM of
triplicate cultures. See Figure 1 for other definitions.

enhance the stimulatory activity of anti–citrullinated
fibrinogen ICs, this time formed with a polyclonal rabbit
antibody against fibrinogen previously demonstrated to
bind native and citrullinated fibrinogen (12) and which
could be targeted by our monoclonal IgM-RF by ELISA
and Western blotting (data not shown). In results analogous to those of previous studies, we observed the
ability of anti–citrullinated fibrinogen ICs to stimulate
macrophage cytokine production and, as with human
RA–derived IgG preparations, the ability of monoclonal

Although several previous studies have demonstrated increased disease activity in the presence of
either anti-CCP or RF, to our knowledge, this study is
the first to identify a synergistic role for ACPAs and RF
in mediating RA-associated inflammation and disease
activity. We demonstrated that baseline autoantibody
status was associated with select measures of disease
activity, both at presentation and over time. Specifically,
joint swelling and higher baseline DAS28 values were
more commonly observed in patients with RA who were
positive for both anti-CCP and RF and, to a lesser extent
in those positive for RF regardless of anti-CCP status.
Interestingly, ESRs were similarly increased in all
autoantibody-positive groups (both double-positive and
single-positive) compared with seronegative patients,
even after accounting for the numerically higher frequency of RA-related treatments used in seropositive
cases; however, values were further increased in the
double-positive group compared with each singlepositive group. The observed increases in disease activity
and the levels of clinical markers of inflammation were
paralleled by a nearly identical pattern of elevation
among several inflammatory cytokines previously associated with RA pathophysiology (26), including those
that we and other investigators have previously demonstrated to be produced in response to macrophage
stimulation by ACPA ICs (12,13).
The increased inflammation and disease activity
observed in the double-positive group is supportive of a
potential role for these RA-associated autoantibodies in
mediating the pathogenesis of RA. However, because
association does not prove causality, we used an in vitro
model of ACPA IC–mediated inflammation to identify a
novel mechanism by which the interaction of ACPAs
and RF may contribute to the pathophysiology of RA
inflammation and disease activity. We thus demonstrate
a unifying mechanism by which the 2 overtly distinct
autoantibody types that characterize RA can interact to
promote RA disease pathogenesis.
RF was first identified by the ability of RA serum
to agglutinate IgG-coated sheep red blood cells, was
subsequently defined as an immunoglobulin targeting
the Fc portion of IgG (3), and is now considered to be
characteristic of the presence of RA and has been
associated with increased disease severity (9,11). How-
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ever, the pathogenic role of RF has been questioned
and, to date, poorly defined. In 1961, Ragan stated that
“the significance of rheumatoid factor in the pathogenesis of rheumatoid arthritis remains conjectural” (3).
More than 50 years later, little progress has been
made in our understanding. Previous studies have suggested the ability of RF to accelerate experimental
models of IC-mediated vascular damage (27), and although there is evidence for the ability of RF to fix
complement (28,29), other studies suggest that RF may
in fact prevent complement activation by IgG ICs, thus
leading to the speculation that the effects of RF are in
fact mediated by attachment to the Fc region of the IgG
molecule rather than complement activation (30). As
such, this study is the first to suggest a mechanistic role
of RF in RA disease propagation. Additionally, it has
long been known that RF is present in the setting of
non-RA immune activation, including most notably,
viral and bacterial infection.
Prior studies have identified the ability of RFexpressing B cells to recognize ICs (but not monomeric
IgG) and to present the retained antigen to T cells (31),
thus enhancing the immune response to foreign antigen.
Therefore, the generation of RF may have a teleological
purpose in its potential ability to stabilize protective ICs.
We propose that soluble RF may have developed to
provide a protective evolutionary advantage against
infectious pathogens. Because the immune response
associated with RA and similar autoimmune conditions
is also associated with the presence of RF, we hypothesize that inflammatory disease pathogenesis has coopted the beneficial role of IC stabilization, thus enhancing the pathogenic capacity of disease-associated
autoantibodies and resultant ICs.
The current study has several limitations. Given
the large proportion of older patients examined (who
are reflective of current VA beneficiaries), caution
should be used before applying these results to a broader
RA patient population. Also, given reports highlighting
the pathogenic role that ACPAs might play in propagating RA-related joint damage (14), further analyses examining the relationship of autoantibody status with
clinical and radiographic outcomes in RA are important.
Despite use of methods optimized to minimize
the effects of heterophilic antibodies, our laboratory
studies do not eliminate the potential of heterophilic
antibodies such as RF to induce erroneously elevated
signal in sandwich immunoassays (32,33). Thus, the risk
remains that the observed elevation of cytokine levels in
the double-positive group is in part a result of such bias.
However, the relative lack of signal in the RF single-
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positive group, as well as supporting clinical and ESR
data, provide evidence against a significant contribution
of such confounding in this study. Finally, the complexity
and heterogeneity of IgM-RF remain great. Although
most monoclonal RF characterized to date target the
C␥2–C␥3 interface in the Fc region on the IgG molecule
(34), the variations in exact binding sites as well as the
role of various posttranslational modifications (35,36) to
affect RF binding, as well as the typically polyclonal
nature of RF in vivo, may limit the generalizability
of our IC data generated with a single monoclonal
IgM-RF.
In summary, our results showed that a significantly increased level of disease activity as well as
increased levels of systemic inflammation markers were
associated with the concordant presence of RF and
ACPAs in a multivariable analysis accounting for a
variety of other potentially associated clinical variables.
Here, we demonstrate a mechanism by which the IgMRF–ACPA interaction may directly contribute to RA
disease pathogenesis. These results not only provide
useful information for predicting the severity of RA but
also, by identifying a mechanistic interaction between
ACPAs and IgM-RF, advance our understanding of the
role of RA-associated autoantibodies in mediating the
pathogenesis of RA.
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